Endothelin antagonists in clinical trials: lessons learned.

@article{Barton2011EndothelinAI,
  title={Endothelin antagonists in clinical trials: lessons learned.},
  author={Matthias Barton and Donald E. Kohan},
  journal={Contributions to nephrology},
  year={2011},
  volume={172},
  pages={
          255-60
        }
}
Over the past 20 years, a large number of endothelin receptor antagonists (ERAs) have been developed, many of which underwent clinical testing. Yet, today only two ERAs are approved for the treatment of only two clinical indications, namely pulmonary arterial hypertension and scleroderma-related digital ulcers. Clinical development of ERAs has been hampered by problems with dosing, with the makeup of study cohorts, and adverse events. More recently, a number of studies evaluated the potential… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Endothelin and the podocyte

  • Clinical kidney journal
  • 2012
VIEW 15 EXCERPTS
CITES BACKGROUND

Collecting duct principal cell transport processes and their regulation.

  • Clinical journal of the American Society of Nephrology : CJASN
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

Flow regulation of endothelin-1 production in the inner medullary collecting duct.

  • American journal of physiology. Renal physiology
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND